Please assess the completion status of the following clinical trial:

Trial Title: NNRTI/PI Toxicity Switch to Darunavir Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected as documented by a licensed HIV-1 antibody ELISA test~* Subject is currently on an antiretroviral regimen comprising of at least three licensed antiretroviral agents including efavirenz, ritonavir-boosted lopinavir or ritonavir-boosted atazanavir~* Subject is virologically suppressed with a viral load \< 50 copies/ml~* Subject has a CD4+ count above 50 cells/ml~* If subject is a female of childbearing potential, she must agree to use a double barrier method of contraception~* No previous exposure to darunavir~Exclusion Criteria:~* Pregnant or lactating women~* Any female of childbearing potential not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARVs)~* Heterosexually active male subject not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and until 30 days after the end of the trial (or after last intake of investigational ARVs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Immediate switch from NNRTI/PI to DRV/r
- Group 2 (Type: ACTIVE_COMPARATOR): Switch after 10 weeks from NNRTI/PI to DRV/r

Based on this trial design, predict the completion outcome and termination type (if applicable).